# The Value of Serum MicroRNA-21-5p and LncRNAgadd7 Expression Levels in Predicting the Severity and Prognosis of ARDS ( Acute Respiratory Distress Syndrome )

> **NCT06825754** · — · COMPLETED · sponsor: **Shao Yuekai** · enrollment: 110 (actual)

## Conditions studied

- Acute Respiratory Distress Syndrome

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06825754
- **Lead sponsor:** Shao Yuekai
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-01
- **Primary completion:** 2024-11-30
- **Final completion:** 2025-01-10
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2025-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06825754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06825754, "The Value of Serum MicroRNA-21-5p and LncRNAgadd7 Expression Levels in Predicting the Severity and Prognosis of ARDS ( Acute Respiratory Distress Syndrome )". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06825754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*